Logo image of 1AKRO.MI

AKERO THERAPEUTICS INC (1AKRO.MI) Stock Fundamental Analysis

Europe - BIT:1AKRO - US00973Y1082 - Common Stock

45.71 EUR
+45.71 (+Infinity%)
Last: 10/20/2025, 7:00:00 PM
Fundamental Rating

2

1AKRO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 76 industry peers in the Biotechnology industry. 1AKRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 1AKRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 1AKRO has reported negative net income.
In the past year 1AKRO has reported a negative cash flow from operations.
1AKRO had negative earnings in each of the past 5 years.
1AKRO had a negative operating cash flow in each of the past 5 years.
1AKRO.MI Yearly Net Income VS EBIT VS OCF VS FCF1AKRO.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

With a Return On Assets value of -25.60%, 1AKRO perfoms like the industry average, outperforming 51.35% of the companies in the same industry.
With a decent Return On Equity value of -27.68%, 1AKRO is doing good in the industry, outperforming 66.22% of the companies in the same industry.
Industry RankSector Rank
ROA -25.6%
ROE -27.68%
ROIC N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
1AKRO.MI Yearly ROA, ROE, ROIC1AKRO.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

1AKRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
1AKRO.MI Yearly Profit, Operating, Gross Margins1AKRO.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for 1AKRO has been increased compared to 1 year ago.
1AKRO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 1AKRO has an improved debt to assets ratio.
1AKRO.MI Yearly Shares Outstanding1AKRO.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
1AKRO.MI Yearly Total Debt VS Total Assets1AKRO.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 29.07 indicates that 1AKRO is not in any danger for bankruptcy at the moment.
1AKRO has a better Altman-Z score (29.07) than 95.95% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that 1AKRO is not too dependend on debt financing.
1AKRO's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. 1AKRO outperforms 68.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 29.07
ROIC/WACCN/A
WACCN/A
1AKRO.MI Yearly LT Debt VS Equity VS FCF1AKRO.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 12.66 indicates that 1AKRO has no problem at all paying its short term obligations.
1AKRO has a better Current ratio (12.66) than 94.59% of its industry peers.
1AKRO has a Quick Ratio of 12.66. This indicates that 1AKRO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.66, 1AKRO belongs to the top of the industry, outperforming 94.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.66
Quick Ratio 12.66
1AKRO.MI Yearly Current Assets VS Current Liabilites1AKRO.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

1AKRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.44%.
EPS 1Y (TTM)-11.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, 1AKRO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.74% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.88%
EPS Next 2Y-5.84%
EPS Next 3Y-6.92%
EPS Next 5Y20.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
1AKRO.MI Yearly Revenue VS Estimates1AKRO.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
1AKRO.MI Yearly EPS VS Estimates1AKRO.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1AKRO. In the last year negative earnings were reported.
Also next year 1AKRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1AKRO.MI Price Earnings VS Forward Price Earnings1AKRO.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1AKRO.MI Per share data1AKRO.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as 1AKRO's earnings are expected to decrease with -6.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.84%
EPS Next 3Y-6.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1AKRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKERO THERAPEUTICS INC

BIT:1AKRO (10/20/2025, 7:00:00 PM)

45.71

+45.71 (+Infinity%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners106.92%
Inst Owner ChangeN/A
Ins Owners1.24%
Ins Owner ChangeN/A
Market Cap3.66B
Revenue(TTM)N/A
Net Income(TTM)-283959000
Analysts84.21
Price Target54.66 (19.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.12%
Min EPS beat(2)7.14%
Max EPS beat(2)9.09%
EPS beat(4)3
Avg EPS beat(4)4.51%
Min EPS beat(4)-13.96%
Max EPS beat(4)15.77%
EPS beat(8)5
Avg EPS beat(8)2.78%
EPS beat(12)8
Avg EPS beat(12)5.49%
EPS beat(16)11
Avg EPS beat(16)6.25%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.13
P/tB 4.13
EV/EBITDA N/A
EPS(TTM)-3.29
EYN/A
EPS(NY)-3.64
Fwd EYN/A
FCF(TTM)-2.73
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS0
BVpS11.08
TBVpS11.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.6%
ROE -27.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.66
Quick Ratio 12.66
Altman-Z 29.07
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.17%
EPS Next Y0.88%
EPS Next 2Y-5.84%
EPS Next 3Y-6.92%
EPS Next 5Y20.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-37.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.39%
EBIT Next 3Y-18.12%
EBIT Next 5YN/A
FCF growth 1Y-160.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.44%
OCF growth 3YN/A
OCF growth 5YN/A

AKERO THERAPEUTICS INC / 1AKRO.MI FAQ

Can you provide the ChartMill fundamental rating for AKERO THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to 1AKRO.MI.


What is the valuation status for 1AKRO stock?

ChartMill assigns a valuation rating of 0 / 10 to AKERO THERAPEUTICS INC (1AKRO.MI). This can be considered as Overvalued.


Can you provide the profitability details for AKERO THERAPEUTICS INC?

AKERO THERAPEUTICS INC (1AKRO.MI) has a profitability rating of 1 / 10.


How financially healthy is AKERO THERAPEUTICS INC?

The financial health rating of AKERO THERAPEUTICS INC (1AKRO.MI) is 6 / 10.